Accelerating Drug Development by Reinventing the How

N-Power Medicine is building the first always-on clinical research system in community oncology to dramatically boost clinical trial participation and realize the promise of prospective external controls to accelerate and de-risk oncology R&D.

Company History

  • AUG 2021

    Founded by pharma drug development executives

  • AUG 2022

    Kaleido Registry Launched

  • JUNE 2024

    Established strategic partnership and investment from Merck & Merck Global Health Innovation Fund

  • JAN 2025

    Completed acquisition of Syapse Holdings, Inc.establishing N-Power as one of the largest community-based prospective clinical research networks

  • MAY 2025

    Launch First Prospective External Control

  • Raised $100M+ to Date from Leading US healthcare Investors

The Leadership Team

  • Mark Lee, MD, PhD

    Mark Lee, MD, PhD

    Chief Executive Officer and Co-Founder

    LinkedIn
  • Jonathan Daniels

    Jonathan Daniels

    Head of Business Development & Partnering

    LinkedIn
  • Maria Ferrari

    Maria Ferrari

    Head of Network Operations & Chief of Staff

    LinkedIn
  • Joey McMurdie

    Joey McMurdie

    Head of Data Science & AI

    LinkedIn

N-Power Medicine
Strategic Advisors

  • Steve Hahn, MD

    Steve Hahn, MD

    24th FDA Commissioner 2019–2021, CEO of Nucleus RadioPharma

    LinkedIn
  • Ned Sharpless, MD

    Ned Sharpless, MD

    15th NCI Director, Acting FDA Commissioner 2019, Managing Director Jupiter BioVentures, Professor UNC Chapel Hill

    LinkedIn
  • Alan Sandler, MD

    Alan Sandler, MD

    Internationally Renowned Leader in Oncology and Drug Development

    LinkedIn
  • Andrea Ferris

    Andrea Ferris

    CEO LUNGevity Foundation

    LinkedIn
  • Barbara McAneny, MD, MACP, FASCO

    Barbara McAneny, MD, MACP, FASCO

    Founder, National Cancer Care Alliance; CEO, New Mexico Cancer Center

    LinkedIn
  • Bradley Malin, PhD

    Bradley Malin, PhD

    Accenture Professor of Biomedical Informatics, Biostatistics, & Computer ScienceVanderbilt University Medical Center

    LinkedIn
  • Christopher Flowers, MD, MSc

    Christopher Flowers, MD, MSc

    Chair and Professor at The University of TexasM.D. Anderson Cancer Center

    LinkedIn
  • Ethan Basch, MD, MSc

    Ethan Basch, MD, MSc

    Chief of Oncology UNC Chapel Hill School of Medicine

    LinkedIn
  • Fabrice André, MD, PhD

    Fabrice André, MD, PhD

    ESMO President-Elect Institut Gustave RoussyDepartment of Medical Oncology

    LinkedIn
  • Jeff Allen, PhD

    Jeff Allen, PhD

    President & CEO Friends of Cancer Research

    LinkedIn
  • Steven Shak, MD

    Steven Shak, MD

    Chief Medical Officer Genomic Life

    LinkedIn